Pricing Log in Create free account
Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue
+58.1%
EPS
+142.2%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

90.90 2.56 +2.90%
Market cap
$6.9B
P/E
62.1×
Fwd P/E
67.8×
Dividend yield
—
F-score
8/9
Altman Z
10.35
Beneish M
−3.16
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 7 added · 2 removed · 24 modified
P2I1A: no changes 		Inventory outpacing revenue
8-K Oct 27, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 17, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Jun 30, 2026
8-K Jul 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 29, 2026 5.07 Submission of matters to a vote of security holders
8-K May 21, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Apr 30, 2026 5.02 Departure or appointment of directors or officers
10-Q Mar 31, 2026
8-K Apr 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 25 added · 28 removed · 121 modified
1A: 70 added · 124 removed · 224 modified
7: 4 added · 24 removed · 44 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 10, 2026 5.02 Departure or appointment of directors or officers
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 3, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 21, 2025 1.02 Termination of a material definitive agreement; 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 9.01 Financial statements and exhibits
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 23, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 23, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 28, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 4, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.